Navigation Links
neuropathic in Medical Technology

Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharma's Product Class

SAN DIEGO, July 13 /PRNewswire/ -- Research published in the June 26, 2009 edition of Proceedings of National Academy of Sciences provides further evidence for novel roles of tRNA synthetases in disease, validating the therapeutic potential for aTyr Pharma's new class of naturally occurring prot...

XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain

VALLEY COTTAGE, N.Y., June 30 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB ; TASE: XTL) today announced that it has completed patient randomization into its Phase 2b study of Bicifadine -- a serotonin and norepinephrine reuptake inhibitor (SNRI) -- for the treatment of ...

New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain

Results presented at the 27th Annual Meeting of the American Pain Society (APS) SMYRNA, Ga., May 8 /PRNewswire/ -- Patients treated with lacosamide demonstrated sustained pain relief from diabetic neuropathic pain (DNP), compared to placebo-treated patients, acco...

Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain

UCB announces clinical data presented at the 60th Annual Meeting of the American Academy of Neurology (AAN) in Chicago SMYRNA, Ga., April 16 /PRNewswire/ -- UCB presented efficacy and safety results from pooled analyses of Phase II and III double-blind, randomized, placebo-controll...

Avanir Pharmaceuticals Announces Positive Results of Phase III Study for Zenvia in Diabetic Neuropathic Pain

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Apr 18, 2007 - Avanir Pharmaceuticals (NASDAQ:AVNR) today announced positive top-line results from the company's Phase III clinical trial evaluating the investigational drug Zenvia(TM) (dextromethorphan hydrobromide/quinidine sulfate ("DMQ")), an NMDA antagonis...

Cephalon Presents Positive Results for Fentora in Breakthrough Pain Associated with Neuropathic Conditions

All Efficacy Measures Reached Statistical Significance FRAZER, Pa., May 01, 2007 /PRNewswire-FirstCall/ -- A Cephalon, Inc. Phase 3 clinical trial presented today at the 59th Annual Meeting of the American Academy of Neurology in Boston highlights data demonstrating that FENTORA(R) (fentan...

AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at Second International Congress on Neuropathic Pain

ALISO VIEJO, Calif.--(BUSINESS WIRE)--May 8, 2007 - AVANIR Pharmaceuticals (NASDAQ:AVNR) today announced Phase III data on the efficacy, safety and improvements in patient-centered outcomes in patients with diabetic peripheral neuropathic (DPN) pain treated with the investigational drug Zenvia(TM) ...

NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)

SAN CARLOS, Calif., June 07, 2007 /PRNewswire-FirstCall/ -- NeurogesX, Inc. announced today the presentation of clinical data from a positive Phase 3 trial in postherpetic neuralgia (PHN). Misha-Miroslav Backonja, M.D., Professor of Neurology at University of Wisconsin in Madison and lead academic...

AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at International Congress on Neuropathic Pain

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Jun 8, 2007 - AVANIR Pharmaceuticals (NASDAQ:AVNR) today announced the presentation of Phase III data, including efficacy, safety and improvements in patient-centered outcomes in patients with diabetic peripheral neuropathic (DPN) pain treated with the investig...

Expert Opinion Highlights Avigen's AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal

Focus On AV411's Unique Mechanism of Action and Broad Potential for the Treatment of Neurological Conditions ALAMEDA, Calif., June 26, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapeutics for the treatment of neurological conditions, announce...

NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study

...rapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), pain...designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, either alone or in co...

Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology

... evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding pr...

Elbit Imaging Ltd. Announces - Swiss Team Uses InSightec's ExAblate(R) 4000 Brain System to Treat Patients With Functional Brain Disorders

...ultrasound surgery (TcMRgFUS) for the treatment of neuropathic pain. Ten adult patients diagnosed with chronic neuropathic pain successfully underwent non-invasive deep brai...dality for functional brain disorders. "The neuropathic pain study performed at Zurich demonstrated the fe...

Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech

... evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo has established strategic partnerships with companies in non-therapeutic...

CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders

...nt is very promising, and we look forward to assessing it in the clinic for neuropathic and neurodegenerative conditions that currently have no treatment options."...fficer of CeNeRx. "Our rapidly aging population is at risk for devastating neuropathic and neurodegenerative diseases that lack effective therapies. We intend to...

NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia

...ation capsaicin dermal patch for the management of neuropathic pain in patients with postherpetic neuralgia (PHN)...rapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), pain...designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in ...

Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy

...he innovative discovery and testing of novel therapeutic compounds in the field of neuroscience to treat epilepsy, depression, anxiety, schizophrenia, neuropathic pain and neurodegenerative disorders. The company has eight new drug candidates in clinical or preclinical development, including their lead compound,...

Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy

...ugh our understanding of the underlying biology of neuropathic pain." Previously published research has shown that in neuropathic pain conditions such as PDN, the signal that trigg...ct pipeline comprises multiple candidates to treat neuropathic pain. ...

Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers

...placebo-controlled study that screened approximately 285 patients at 30 U.S. medical centers and recruited more than 120 patients with lower extremity neuropathic ulcers that were chronically non-healing despite receiving standard of care. The study is designed to evaluate safety and efficacy in patients receivi...

Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences

... evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding pr...

Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study

...ment of generalized anxiety disorder, the management of diabetic peripheral neuropathic pain and the management of fibromyalgia, all in adults (18+). Cymbalta is n...ve disorder and generalized anxiety disorder and manage diabetic peripheral neuropathic pain. Antidepressants can increase suicidal thoughts and behaviors in child...

Advances in Science and Treatment of Pain Presented at 25th Annual American Academy of Pain Medicine Meeting January 28 - 31, 2009

...Ballroom Foyer, Hilton Hawaiian Village Authors present Jan. 29 from 3:30-5 PM and Jan. 30 from 9-10 AM Calcium Channel Blockers Compared for neuropathic Pain, Poster 181 Addictive Qualities of Cannabinoid Medication, Poster 193 Tramadol Outcomes, Poster 197 Safety, Tolerability and Effectiv...

NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology

...nes Agency (EMEA) for the management of peripheral neuropathic pain. The paper in The Lancet Neurology tit...rapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), pain...designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers ...

Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain

...CR845 was highly selective for the peripheral kappa opioid receptor. Animal studies indicate that CR845 is effective in treating pain of inflammatory, neuropathic and visceral origin and exhibited analgesic efficacy for up to 18 hours after a single dose. Analgesic activity was seen after intravenous, subcutaneo...

Sosei Confirms the Safety of SD118 in Two Phase I Trials

...(DRP), it has demonstrated potential as a new oral neuropathic pain therapy. The Phase I trials were both...lopment." Notes for Editors: About neuropathic Pain neuropathic pain is caused by a primary lesion or dysfunction ...

Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives

...on of safety and clinical effect in patients with diabetic neuropathy and ALS. Other therapeutic development programs are focused on cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding pro...

Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain

...nxiety disorder, management of diabetic peripheral neuropathic pain and management of fibromyalgia. Lilly...isorder, and the management of diabetic peripheral neuropathic pain and fibromyalgia in adults age 18 years and o...nxiety disorder, and to manage diabetic peripheral neuropathic pain and fibromyalgia. Antidepressants can increas...

Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting

...is investigational drug is a potential therapy for neuropathic pain and has successfully completed Phase I clinic...uropathy and chronic constriction injury models of neuropathic hypersensitivity and suggest that this compound may be effective in treating neuropathic pain in man. NSL-043/SD118 is being jointl...

Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I

...with PL37, its lead compound for oral treatment of neuropathic pain. neuropathic pain is a major chronic pain condition, with an es...nd well to usual painkillers. Worldwide market for neuropathic pain is estimated to reach 5 billion USD by 2010. ...

Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain

...s in these trials were treated for up to 18 months and had a broad range of underlying chronic pain conditions, including chronic low back and chronic neuropathic pain. In these trials, opioid-tolerant patients with chronic pain treated with FENTORA experienced statistically significant improvements in relief fr...

Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)

...on of safety and clinical effect in patients with diabetic neuropathy and ALS. Other therapeutic development programs are focused on cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding pro...

Shingles Pain Treatment Will Benefit More Patients

...sentation: Versatis is a medicated plaster (10cm x 14cm) containing 700 mg (5% w/w) of lidocaine in an aqueous adhesive base. Indication: Treatment of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN). Dosage and method of administration: Adults and elderly patients...

Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845

...ion relative to Cara's first generation of peripheral kappa opioids. Animal studies indicate that CR845 is effective in reducing pain of inflammatory, neuropathic and visceral origin. The analgesic and anti-inflammatory effects of CR845 lasted for up to 18 hours after a single dose. CR845 was active after intrav...

Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156

...dress major unmet medical needs. In addition to AEG35156, Aegera has three additional programs in clinical development for the treatment of cancer and neuropathic pain. Details of these programs can be found on Aegera's website at http://www.aegera.com . About The Leukemia & Lymphoma Society The Leukemia & ...

NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation

...f capsaicin designed to treat pain associated with neuropathic pain conditions. The objective of the NGX-1998 dev...rapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), pain...designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers ...

Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel

...d disorders. These include migraine and other forms of chronic pain such as neuropathic pain and fibromyalgia, as well as muscle spasticity and rigidity, thrombosi...ampanel as a treatment for migraine and other forms of chronic pain such as neuropathic pain and fibromyalgia, as well as muscle spasticity and rigidity, thrombosi...

European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder

... major depressive disorder and diabetic peripheral neuropathic pain. Duloxetine gained marketing authorisation fo...he treatment of depression and diabetic peripheral neuropathic pain, in many countries and is approved in some co...e, insomnia, diarrhea -- For diabetic peripheral neuropathic pain: Nausea, somnolence (sleepiness), fatigue, he...

TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate

...d disorders. These include migraine and other forms of chronic pain such as neuropathic pain as well as muscle spasticity and rigidity secondary to spinal cord tra...d NGX426 as treatments for migraine and other forms of chronic pain such as neuropathic pain as well as muscle spasticity and rigidity secondary to spinal cord tra...

Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study

...Important Safety Information Cymbalta is approved to treat major depressive disorder and generalized anxiety disorder and manage diabetic peripheral neuropathic pain. Antidepressants can increase suicidal thoughts and behaviors in children, adolescents and young adults. Patients should call their doctor right ...

NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology

...novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory po...NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages ov...
Other Tags
(Date:4/17/2014)... NY, April 17, 2014The development of stem cell therapies ... ability to characterize stem cell populations based on cell ... discovered a new marker that is highly expressed in ... cord blood, which they describe in an article in ... Mary Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... births, Down syndrome - or trisomy 21 - is ... results from a chromosomal abnormality where cells of affected ... of the human genome). A study conducted by Stylianos ... Medicine and Development at the University of Geneva (UNIGE) ... light on how the extra chromosome 21 upsets the ...
(Date:4/17/2014)... White House honored Clemson professor Rajendra Singh Thursday ... to promote and expand solar deployment in the ... D. Houser Banks Professor of Electrical and Computer ... Nanoelectronics, is considered a local hero leading the ... economic opportunity in solar power and driving policy ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3White House honors Clemson professor as 'Champion of Change' for solar deployment 2
(Date:4/17/2014)... California, San Diego School of Medicine report that older ... recent major loss are more likely to be compassionate ... is published in this month,s issue of the ... behaviors are associated with better health and well-being as ... to improve the outcomes of individuals whose deficits in ...
(Date:4/17/2014)... synthetic biology team has created a new technology ... that could travel the body and selectively target ... cell-based, biological devices that monitor and modify human ... biology. However, no existing technology enabled bioengineers to ... state and respond in a customized fashion. , ...
(Date:4/17/2014)... (April 16, 2014) The cause of neuronal death ... study proposes that neurons may be mistaken for foreign ... similar to the way autoimmune diseases like type I ... cells. The study was published April 16, 2014, in ... and likely controversial, idea in Parkinson,s disease; but if ...
(Date:4/17/2014)... YORK April 17, 2014 EcoHealth Alliance, a ... health issues, published a comprehensive review today examining the ... Marburg virus. The review calls for improved global surveillance ... as the recent outbreak of Ebola in West Africa ... the countries of Guinea and Liberia. According to ...
(Date:4/17/2014)... Population Council scientists and their partners have found that ... prevent the transmission of multiple sexually transmitted infections (STIs) ... herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV). ... the gel is effective against multiple strains of HIV, ... against all three viruses of at least eight hours ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
Other Contents